Elevance Health Inc. ($ELV) Stock Forecast: Down 4.9% Today

What is Elevance Health Inc.?

Asset Elevance Health (ELV) is a health insurance company listed on the NYSE. The company has recently faced regulatory challenges from the Centers for Medicare & Medicaid Services (CMS), leading to a bearish market movement.

Why is Elevance Health Inc. going down?

ELV stock is down 4.9% on Mar 2, 2026 17:35

• The bearish movement in Elevance Health's stock today is linked to CMS imposing sanctions on the company, suspending Medicare enrollment for alleged noncompliance with risk adjustment data submission requirements.
• Despite surpassing quarterly EPS estimates and increasing its dividend, the adverse impact of CMS sanctions appears to overshadow the positive financial performance.
• The contrasting actions of institutional investors, with one increasing its stake significantly while another reducing its holdings, may have contributed to the uncertainty surrounding the stock.
• Elevance Health's efforts to collaborate with CMS and address compliance issues are acknowledged, but market sentiment seems cautious due to impending sanctions impacting the company's Medicare Advantage plans.

ELV Price Chart

ELV Technical Analysis

ELV News

Elevance Health - On Feb 27, CMS To Impose Sanctions On Elevance Health Suspending Medicare Enrollment - SEC Filing

The Centers for Medicare & Medicaid Services (CMS) is set to impose sanctions on Elevance Health on February 27, which will include the suspension of Medicare enrollment. This information comes from a recent SEC filing. The article, while brief, highlights regulatory action against the health insurance giant.

https://www.tradingview.com/news/reuters.com,2026:newsml_FWN3ZQ0Q3:0-elevance-health-on-feb-27-cms-to-impose-sanctions-on-elevance-health-suspending-medicare-enrollment-sec-filing/

Kingsview Wealth Management LLC Buys 16,552 Shares of Elevance Health, Inc. $ELV

Kingsview Wealth Management LLC significantly increased its stake in Elevance Health (NYSE:ELV) by 67.8%, acquiring an additional 16,552 shares to bring its total holdings to 40,975 shares valued at approximately $13.24 million. This comes after Elevance Health exceeded quarterly EPS estimates and raised its quarterly dividend. Institutional investors collectively own 89.24% of the stock.

https://www.marketbeat.com/instant-alerts/filing-kingsview-wealth-management-llc-buys-16552-shares-of-elevance-health-inc-elv-2026-03-02/

Erste Asset Management GmbH Sells 8,193 Shares of Elevance Health, Inc. $ELV

Erste Asset Management GmbH reduced its stake in Elevance Health, Inc. (NYSE:ELV) by 62.0% in the third quarter, selling 8,193 shares and holding 5,011 shares valued at $1.635 million. Despite this, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $390.55. Elevance Health recently surpassed EPS estimates, with revenue slightly below forecasts, and increased its quarterly dividend to $1.72 per share.

https://www.marketbeat.com/instant-alerts/filing-erste-asset-management-gmbh-sells-8193-shares-of-elevance-health-inc-elv-2026-03-02/

CMS plans sanctions on Elevance Health (NYSE: ELV) Medicare Advantage-PD enrollment

The Centers for Medicare & Medicaid Services (CMS) plans to impose intermediate sanctions on Elevance Health's Medicare Advantage-Prescription Drug (MA-PD) plans, suspending new enrollment and certain communications beginning March 31, 2026. These sanctions stem from alleged noncompliance with Medicare Advantage risk adjustment data submission requirements for services prior to April 3, 2023. Elevance Health has revised its practices since April 2023 and is working cooperatively with CMS to resolve the issues, noting that current members' benefits are not affected.

https://www.stocktitan.net/sec-filings/ELV/8-k-elevance-health-inc-reports-material-event-d402782ef95c.html

CMS notifies Elevance Health of intent to sanction Medicare Advantage plans

The Centers for Medicare & Medicaid Services (CMS) has notified Elevance Health (NYSE:ELV) of its intent to impose sanctions on the company's Medicare Advantage-Prescription Drug (MA-PD) plans. These sanctions, set to take effect on March 31, would suspend new enrollments and restrict communications, stemming from alleged noncompliance with risk adjustment data submission requirements prior to April 2023. Elevance Health is engaging with CMS to address these concerns, noting that current MA-PD members' benefits are unaffected, and has already revised relevant practices.

https://m.investing.com/news/sec-filings/cms-notifies-elevance-health-of-intent-to-sanction-medicare-advantage-plans-93CH-4534056?ampMode=1

Trending Today

Cleveland-Cliffs Inc. ($CLF) Stock Forecast: Up 5.9% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Up 5.4% Today

Paysafe Limited ($PSFE) Stock Forecast: Up 5.4% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Up 5.1% Today

StoneCo Ltd. ($STNE) Stock Forecast: Up 5.0% Today

Draftkings Inc ($DKNG) Stock Forecast: Up 5.1% Today

SL Green Realty Corp ($SLG) Stock Forecast: Up 5.0% Today

Eastman Chemical Company ($EMN) Stock Forecast: Up 5.1% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Up 5.1% Today

WESCO International, Inc. ($WCC) Stock Forecast: Up 5.1% Today

Elevance Health Inc. Price History

24.01.2026 - ELV Stock was down 5.2%

• The bearish movement in ELV stock could be attributed to profit-taking by investors after a recent bullish run or concerns about the company's growth prospects.
• The commitment of Elevance Health Foundation to funding food as medicine programs may have diverted investor attention away from ELV, impacting its stock performance negatively.
• Investors may be cautious about ELV's position in the market following news of competitors like Alignment Healthcare reporting membership gains and positive earnings growth.
• The broader market sentiment influenced by news of Humana's weaker earnings outlook and regulatory risks may have also contributed to the bearish trend in ELV stock.

05.00.2026 - ELV Stock was up 1.3%

• ELV stock saw a positive movement today, possibly influenced by favorable updates regarding its collaboration with American Well.
• The extension of the partnership with American Well under new three-year agreements represents a significant benefit for ELV, signaling continued growth potential in digital healthcare.
• The robust Q3 earnings results, surpassing expectations with strong EPS and revenue numbers, also played a role in the positive market sentiment towards Elevance Health.
• In summary, the mix of enhanced partnership agreements and impressive financial performance likely boosted investor confidence in ELV, resulting in the upward movement in the market.

27.00.2026 - ELV Stock was down 8.1%

• Vanguard Personalized Indexing Management LLC and Barlow Wealth Partners Inc. notably decreased their holdings in Elevance Health, aligning with the downward market trend.
• A proposed flat Medicare Advantage payment rate increase by the Trump administration for 2027, falling short of expectations, has impacted Elevance Health and other major health insurers, leading to a decline in stock value.
• While some institutional investors like Whittier Trust Co. divested their shares, Norges Bank and Vanguard Group increased their positions, reflecting mixed investor sentiment.
• The regulatory announcement's potential effects on Humana and other insurers have added to the negative market sentiment in the healthcare sector and influenced Elevance Health's stock performance.

27.00.2026 - ELV Stock was down 12.4%

• The bearish movement in ELV's stock can be attributed to the proposed flat rates for Medicare Advantage plans by the government, impacting major health insurers.
• Recent decisions by health insurers to adjust Medicare Advantage benefits and underwhelming Q4 performance reports have contributed to negative sentiment in the sector.
• Institutional investors have shown varying stances on ELV, with some reducing their stake while others increasing their position.
• The regulatory announcement regarding Medicare payment rate increases for 2027 has put pressure on healthcare companies reliant on Medicare Advantage plans, leading to a bearish trend in ELV's stock price.

27.00.2026 - ELV Stock was down 14.2%

• Elevance Health (ELV) experienced a strong bearish movement likely due to the broader sector-wide selloff following proposed changes in Medicare Advantage payment rates for 2027.
• The reduction in Medicare Advantage benefits by other companies, in response to disappointing reimbursement rates, further added to the negative sentiment surrounding healthcare stocks, including ELV.
• A reduction in stake by an institutional investor in Elevance Health could have also contributed to the downward pressure on the stock, signaling decreased institutional confidence in the company amidst regulatory uncertainty and market volatility.
• The upcoming earnings report of another company, and its recent poor financial performance leading to a new 52-week low, might have influenced investor sentiment towards riskier assets like ELV, contributing to the bearish movement.

28.00.2026 - ELV Stock was up 5.4%

• Elevance Health (ELV) saw a strong bullish movement following a positive reaction to surpassing profit expectations for Q4 2025.
• Despite a mix of results with profits exceeding expectations but revenues falling short investor confidence surged as the company focuses on affordability and platform enhancements.
• Analysts and investors found reassurance in the company's ability to outperform profit expectations and maintain a positive earnings per share outlook for 2026 amidst revenue growth challenges and margin pressures.
• The market shift may have been influenced by general sentiment towards the healthcare and insurance sectors, weighing concerns about margin risks and membership attrition against the company's profit beat and earnings forecast.

28.00.2026 - ELV Stock was up 5.1%

• ELV stock saw an upward trend driven by investors' favorable response to the company exceeding profit expectations in the fourth quarter of 2025.
• The strong performance in earnings per share, which outperformed analyst predictions, likely contributed to the optimistic market sentiment.
• Despite falling short of revenue targets, the emphasis on affordability and the earnings per share guidance of at least $25.50 for 2026 may have reassured investors about the company's future trajectory.
• Positive analyst evaluations and market outlooks appeared to have boosted investor confidence in ELV, influencing the bullish movement in the market.

27.01.2026 - ELV Stock was down 5.5%

• Speculations arose relating to investor concerns prompted by Close Asset Management Ltd's substantial reduction in ELV shares, potentially influencing the bearish market trend.
• The stock's reaffirmed 2026 earnings outlook might not have resonated positively with investors, resulting in a lack of favorable sentiment towards the company.
• Despite Elevance Health's emphasis on responsible AI integration and financial openness, negative market response to the management reshuffle announcements may indicate investor hesitancy.
• The focus on an educational seminar collaboration between Amlan International and Elanco could have diverted attention from Elevance Health, negatively affecting its stock performance as investors turned towards other industry players.

15.00.2026 - ELV Stock was up 1.4%

• Insiders at Elevance Health sold a significant amount of shares, raising concerns among investors despite reasonable insider ownership.
• ELV's price target was raised, citing a slowdown in healthcare utilization growth, indicating a peak in demand.
• A reduction in stake in ELV was noted, but the company exceeded Q3 earnings expectations, maintaining a "Moderate Buy" rating.
• UnitedHealth's announcement of speeding Medicare Advantage payments for rural hospitals may have positively impacted ELV's stock, as it signals potential growth and innovation in the healthcare sector.

12.01.2026 - ELV Stock was up 4.2%

• ELV stock showed a significant bullish movement recently, potentially influenced by various factors:
• Wealthfront Advisers LLC notably increased its stake in ELV, suggesting optimism regarding the company's future prospects and financial performance.
• Although Zacks Research lowered its EPS forecast, ELV surpassed earnings expectations in the last quarter, raised its dividend, likely boosting investor confidence.
• Analysts' "Moderate Buy" rating and an average price target of $390.55 indicate a positive sentiment towards ELV, potentially contributing to the recent stock movement.
• The company's ability to maintain robust performance despite challenges from a shrinking customer base demonstrates resilience and growth potential, appealing to investors seeking opportunities in a competitive market.

02.02.2026 - ELV Stock was down 4.9%

• The bearish movement in Elevance Health's stock today is linked to CMS imposing sanctions on the company, suspending Medicare enrollment for alleged noncompliance with risk adjustment data submission requirements.
• Despite surpassing quarterly EPS estimates and increasing its dividend, the adverse impact of CMS sanctions appears to overshadow the positive financial performance.
• The contrasting actions of institutional investors, with one increasing its stake significantly while another reducing its holdings, may have contributed to the uncertainty surrounding the stock.
• Elevance Health's efforts to collaborate with CMS and address compliance issues are acknowledged, but market sentiment seems cautious due to impending sanctions impacting the company's Medicare Advantage plans.

02.00.2026 - ELV Stock was up 1.0%

• ELV's stock showed a strong bullish movement recently.
• Significant new investment in ELV was made during the third quarter, reflecting confidence in the company's future prospects.
• ELV reported impressive Q3 earnings, surpassing expectations.
• Investors are keeping a close eye on ELV's performance and upcoming earnings release to assess the impact of their capital allocation strategies on shareholder returns.